EMQN best practice guidelines for genetic testing in dystrophinopathies

<jats:title>Abstract</jats:title><jats:p>Dystrophinopathies are X-linked diseases, including Duchenne muscular dystrophy and Becker muscular dystrophy, due to <jats:italic>DMD</jats:italic> gene variants. In recent years, the application of new genetic technologies and the availability of new personalised drugs have influenced diagnostic genetic testing for dystrophinopathies. Therefore, these European best practice guidelines for genetic testing in dystrophinopathies have been produced to update previous guidelines published in 2010.</jats:p><jats:p>These guidelines summarise current recommended technologies and methodologies for analysis of the <jats:italic>DMD</jats:italic> gene, including testing for deletions and duplications of one or more exons, small variant detection and RNA analysis. Genetic testing strategies for diagnosis, carrier testing and prenatal diagnosis (including non-invasive prenatal diagnosis) are then outlined. Guidelines for sequence variant annotation and interpretation are provided, followed by recommendations for reporting results of all categories of testing. Finally, atypical findings (such as non-contiguous deletions and dual <jats:italic>DMD</jats:italic> variants), implications for personalised medicine and clinical trials and incidental findings (identification of <jats:italic>DMD</jats:italic> gene variants in patients where a clinical diagnosis of dystrophinopathy has not been considered or suspected) are discussed.</jats:p>